Short answer
Abbott Laboratories (ABT) filed an 8-K current report with the SEC on October 21, 2026 reporting Item 8.01 (Other Events), Item EX-99.1 (Exhibit EX-99.1). Planned separation of global nutrition business into an independent, publicly traded company.
Abbott Laboratories 8-K event analysis
AI summary of each reported item and its exhibits
Item 8.01 · Other Events
- Planned separation of global nutrition business into an independent, publicly traded company
- Potential portfolio simplification, allowing Abbott to focus on remaining healthcare businesses
- Exhibit 99.1 contains the announcement’s transaction details and expected timeline
Item EX-99.1 · Exhibit EX-99.1
- Planned tax-free spin-off gives Abbott shareholders shares in both companies, subject to approvals and Form 10 effectiveness
- Nutrition business targets independence by end-2027, with approximately $8.5B sales, 16,000 employees and 14 manufacturing sites
- Post-separation Abbott expected to retain approximately $42B sales and focus on devices, diagnostics, biowearables and established medicines
- Combined dividends expected to equal Abbott’s dividend at separation, while one-time transaction charges remain forthcoming
- Daniel Salvadori designated CEO of the new Nutrition company, reducing leadership uncertainty ahead of separation
Generated from the filing text and exhibits; verify against the original. What 8-K item codes mean
Other Abbott Laboratories 8-K filings
Get the next ABT 8-K as it lands
Follow ABT for push alerts, or ask the research agent what this filing means.